Table 2.
Association of baseline total bilirubin with incident NAFLD as measured by FLI
| Total bilirubin level (µmol/l) | Events/total | Model 1 | Model 2 | Model 3 | Model 4 | ||||
|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | ||
| Per 1 SD increase | 434/3824 | 0.72 (0.64 to 0.80) | < 0.001 | 0.78 (0.69 to 0.87) | < 0.001 | 0.77 (0.69 to 0.87) | < 0.001 | 0.82 (0.73 to 0.92) | 0.001 |
| T1 (0.95–6) | 208/1627 | Ref. | Ref. | Ref. | Ref. | ||||
| T2 (7, 8) | 116/1024 | 0.70 (0.55 to 0.90) | 0.006 | 0.85 (0.65 to 1.10) | 0.209 | 0.85 (0.66 to 1.11) | 0.232 | 0.92 (0.71 to 1.20) | 0.536 |
| T3 (≥ 9) | 110/1173 | 0.51 (0.39 to 0.66) | < 0.001 | 0.62 (0.47 to 0.81) | < 0.001 | 0.61 (0.47 to 0.80) | < 0.001 | 0.69 (0.52 to 0.91) | 0.008 |
2420 participants with prevalent NAFLD as measured by FLI were excluded
CI confidence interval, FLI fatty liver index, NAFLD non-alcoholic fatty liver disease, OR odds ratio, SD standard deviation, T tertile
Model 1: Age and sex
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol
Model 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and loge urinary albumin excretion
Model 4: Model 3 plus loge high-sensitivity C-reactive protein